Veracyte (VCYT) released fresh data from the randomized BALANCE study at ASTRO 2025, showing its PAM50 molecular signature can identify which prostate cancer patients benefit from adding hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback